Nasal Spray

FDA grants approval for OTC opioid overdose treatment

03-Apr-2023 By Ben Hargreaves

The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.

Aptar announces ‘highly recyclable’ nasal spray

06-Feb-2023 By Ben Hargreaves

The company outlines that has designed a nasal spray pump that uses no metal parts to deliver OTC formulations.

Emergent receives FDA priority review for OTC naloxone spray

12-Dec-2022 By Ben Hargreaves

Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.

Impel Pharmaceuticals upper-nasal delivery offers hope for migraine patients

26-Apr-2022 By Jenni Spinner

The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.

Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study

28-Sep-2020 By Rachel Arthur

Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.

Reckitt Benckiser to co-develop nasal spray to treat opioid overdose

20-May-2014 By Zachary Brennan

Reckitt Benckiser and AntiOp announced plans on Monday to co-develop a naloxone nasal spray to help in the reversal of opioid overdose.

Nastech delays osteoporosis nasal spray development

06-Dec-2006 By Emilie Reymond

Nastech missed out on a $15m (€11m) milestone payment after having
to delay the development of its new nasal spray for the treatment
of osteoporosis because of the need of an additional clinical
trial.

Valois uses Malvern's technology for novel nasal spray

26-Jun-2006 By Kirsty Barnes

UK-based Malvern Instruments has revealed that its next-generation
particle size analysis system is being used by French contract
manufacturer Valois in the validation of its unique nasal spray
device.

Nastech secures manufacturing contract for new needle free osteoporosis drug

12-Jun-2006 By Kirsty Barnes

Nastech has secured a contract with Procter & Gamble (P&G)
to ramp up manufacturing capacity for a new needle-free drug to
beat osteoporosis, in anticipation of meeting expected global
demand once the product is approved.

Procter to develop Nastech osteoporosis drug

15-Feb-2006 By Gregory Roumeliotis

Biotechnology firm Nastech has chosen Procter & Gamble to
develop and commercialise its osteoporosis nasal spray worldwide,
in a lucrative deal that could reach $577m (€480m) over the life of
the project and give both companies...